DaVita Inc. (DVA)
NYSE • Healthcare
September 10, 2026 at 16:24 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, DaVita Inc. keeps $7 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 28
in 48 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
DaVita beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 4, as revenue rose 5.2% to about $3.6 billion and adjusted EPS came in at $4.02. Revenue of about $3.6 billion topped the about $3.5 billion consensus by 1.7%, while EPS of $4.02 beat the $3.88 estimate by 3.6% and was up from $2.95 a year ago. Net income increased 33.1% to about $265 million from $199.3 million a year earlier, and operating income reached about $579 million. Operating cash flow was about $490 million, and DaVita returned capital with about $364 million of stock repurchases and about $150 million in dividends. For the next period, consensus calls for EPS of $3.92 on revenue of $3.53 billion.
About DaVita Inc.
DaVita Inc. (NYSE: DVA) provides kidney dialysis treatments and broader renal care services in the healthcare sector, centered on outpatient, hospital, and home settings. The company generated $13.6 billion in FY2025 revenue. It serves patients with chronic kidney failure and related end-stage renal disease needs across the United States and ten countries outside the U.S.
Today's Snapshot
DVA opened slightly higher at 183.62, while its sector was flat.
Trading Volume
Below 10d avg (524.4K)
84.1K
vs S&P 500 Today
Moderate Underperformance
-0.30%
Updated: September 10, 2026 at 14:50 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$168.33 - $193.37Sell
- RSI (14)42.39Neutral
- Stochastic %K (14, 3, 3)74.48Neutral
- MACD Level (12, 26)-5.56Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.